Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia

- Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch – – Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 – SAN FRANCISCO and GENEVA…Read More »

Amarantus Reports First Quarter 2015 Financial Results and Business Overview

- Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 – – Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT – SAN FRANCISCO and GENEVA, May 2…Read More »

Amarantus to Present at Two Upcoming Investor Conferences

-Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT- -LD Micro Invitational Presentation and Webcast on June 2, 2015, at 1:30 p.m. EDT / 10:30 a.m. PDT- SAN FRA…Read More »

Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease

Collaboration Using Renishaw Plc’s Convection-Enhanced Delivery Device Demonstrated MANF Can be Precisely Delivered to Parkinson’s-Associated Brain Areas Delivery and Distribution Data Solidifies Rati…Read More »

Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies

- Catalent to Utilize Proprietary GPEx® Platform for Production of High Performance MANF Expressing Cell Line – – cGMP Production of MANF to Enable Program Advancement Into Human Clinical Studies in R…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111
Phone: (415) 688-4484
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Jenene Thomas Communications, LLC
Jenene Thomas, Investor Relations and Corporate Communications Advisor
Phone: (908) 938-1475
jenene@jenenethomascommunications.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts